Literature DB >> 19383346

Impact of cytogenetic and genomic aberrations of the kallikrein locus in ovarian cancer.

Jane Bayani1, Miltiadis Paliouras, Chris Planque, Shannon J C Shan, Cassandra Graham, Jeremy A Squire, Eleftherios P Diamandis.   

Abstract

The tissue kallikrein (KLK) genes are a new source for biomarkers in ovarian cancer. However, there has been no systematic analysis of copy number and structural rearrangements related to their protein expression. Chromosomal rearrangements and copy number changes of the KLK region were studied by FISH with protein levels measured by ELISA. Ovarian cancer and cell lines revealed the KLK region was subject to copy number imbalances or involved in unbalanced translocations and were associated with increased protein expression of KLKs 5, 6, 7, 8, 9, 10 and 11. In this initial study, we introduce the potential for long-range chromosomal effects and copy number as a mechanism for the previously reported aberrant expression of many KLK genes in ovarian cancers.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19383346      PMCID： PMC5527811          DOI： 10.1016/j.molonc.2008.07.001

Source DB:  PubMed          Journal:  Mol Oncol        ISSN： 1574-7891            Impact factor:   6.603


  43 in total

1.  Aberrations of chromosome 8 in 16 breast cancer cell lines by comparative genomic hybridization, fluorescence in situ hybridization, and spectral karyotyping.

Authors:  J Rummukainen; S Kytölä; R Karhu; F Farnebo; C Larsson; J J Isola
Journal:  Cancer Genet Cytogenet       Date:  2001-04-01

2.  Influences of chromosome size, gene density and nuclear position on the frequency of constitutional translocations in the human population.

Authors:  Wendy A Bickmore; Peter Teague
Journal:  Chromosome Res       Date:  2002       Impact factor: 5.239

3.  The epigenetic basis for the aberrant expression of kallikreins in human cancers.

Authors:  Georgios Pampalakis; Eleftherios P Diamandis; Georgia Sotiropoulou
Journal:  Biol Chem       Date:  2006-06       Impact factor: 3.915

4.  The distribution of CpG islands in mammalian chromosomes.

Authors:  J M Craig; W A Bickmore
Journal:  Nat Genet       Date:  1994-07       Impact factor: 38.330

5.  Multicolor spectral karyotyping of serous ovarian adenocarcinoma.

Authors:  Pulivarthi H Rao; Charles P Harris; Xin Yan Lu; Xiao-Nan Li; Samuel C Mok; Ching C Lau
Journal:  Genes Chromosomes Cancer       Date:  2002-02       Impact factor: 5.006

6.  Genomic organization of the human kallikrein gene family on chromosome 19q13.3-q13.4.

Authors:  G M Yousef; A Chang; A Scorilas; E P Diamandis
Journal:  Biochem Biophys Res Commun       Date:  2000-09-16       Impact factor: 3.575

7.  Human kallikrein 6 degrades extracellular matrix proteins and may enhance the metastatic potential of tumour cells.

Authors:  Manik C Ghosh; Linda Grass; Antoninus Soosaipillai; Georgia Sotiropoulou; Eleftherios P Diamandis
Journal:  Tumour Biol       Date:  2004 Jul-Aug

Review 8.  Human tissue kallikreins: a family of new cancer biomarkers.

Authors:  Eleftherios P Diamandis; George M Yousef
Journal:  Clin Chem       Date:  2002-08       Impact factor: 8.327

9.  Association of KLK5 overexpression with invasiveness of urinary bladder carcinoma cells.

Authors:  Yasuo Shinoda; Ken-Ichi Kozaki; Issei Imoto; Wataru Obara; Hitoshi Tsuda; Yoichi Mizutani; Taro Shuin; Tomoaki Fujioka; Tsuneharu Miki; Johji Inazawa
Journal:  Cancer Sci       Date:  2007-04-24       Impact factor: 6.716

10.  Chromosome analysis of 97 primary breast carcinomas: identification of eight karyotypic subgroups.

Authors:  N Pandis; Y Jin; L Gorunova; C Petersson; G Bardi; I Idvall; B Johansson; C Ingvar; N Mandahl; F Mitelman
Journal:  Genes Chromosomes Cancer       Date:  1995-03       Impact factor: 5.006
View more
  8 in total

1.  Overexpression of kallikrein gene 10 is a biomarker for predicting poor prognosis in gastric cancer.

Authors:  Xin Jiao; Hong-Jun Lu; Mi-Mi Zhai; Zhi-Jun Tan; Hai-Ning Zhi; Xiao-Man Liu; Chen-Hao Liu; Da-Peng Zhang
Journal:  World J Gastroenterol       Date:  2013-12-28       Impact factor: 5.742

2.  Genomic instability and copy-number heterogeneity of chromosome 19q, including the kallikrein locus, in ovarian carcinomas.

Authors:  Jane Bayani; Paula Marrano; Cassandra Graham; Yingye Zheng; Lin Li; Dionyssios Katsaros; Heini Lassus; Ralf Butzow; Jeremy A Squire; Eleftherios P Diamandis
Journal:  Mol Oncol       Date:  2010-08-11       Impact factor: 6.603

3.  Three dysregulated miRNAs control kallikrein 10 expression and cell proliferation in ovarian cancer.

Authors:  N M A White; T-F F Chow; S Mejia-Guerrero; M Diamandis; Y Rofael; H Faragalla; M Mankaruous; M Gabril; A Girgis; G M Yousef
Journal:  Br J Cancer       Date:  2010-03-30       Impact factor: 7.640

4.  Impact of cytogenetic and genomic aberrations of the kallikrein locus in ovarian cancer.

Authors:  Jane Bayani; Miltiadis Paliouras; Chris Planque; Shannon J C Shan; Cassandra Graham; Jeremy A Squire; Eleftherios P Diamandis
Journal:  Mol Oncol       Date:  2008-07-22       Impact factor: 6.603

Review 5.  Functional roles of human kallikrein-related peptidases.

Authors:  Georgia Sotiropoulou; Georgios Pampalakis; Eleftherios P Diamandis
Journal:  J Biol Chem       Date:  2009-10-09       Impact factor: 5.157

6.  Clinical relevance of kallikrein-related peptidase 6 (KLK6) and 8 (KLK8) mRNA expression in advanced serous ovarian cancer.

Authors:  Nancy Ahmed; Julia Dorn; Rudolf Napieralski; Enken Drecoll; Matthias Kotzsch; Peter Goettig; Eman Zein; Stefanie Avril; Marion Kiechle; Eleftherios P Diamandis; Manfred Schmitt; Viktor Magdolen
Journal:  Biol Chem       Date:  2016-12-01       Impact factor: 3.915

7.  Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways.

Authors:  Donavon Hiss
Journal:  J Oncol       Date:  2012-02-06       Impact factor: 4.375

8.  Kallikrein-related peptidase 6 regulates epithelial-to-mesenchymal transition and serves as prognostic biomarker for head and neck squamous cell carcinoma patients.

Authors:  Carola H Schrader; Markus Kolb; Karim Zaoui; Christa Flechtenmacher; Niels Grabe; Klaus-Josef Weber; Thomas Hielscher; Peter K Plinkert; Jochen Hess
Journal:  Mol Cancer       Date:  2015-05-20       Impact factor: 27.401
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.